publications and conference presentations.
evidence informs insight. insight drives impact.
advancing the drug development landscape.
Through the years, we have amassed an extensive clinical database for WEE1 inhibition, which has provided deep insights into optimal dosing, safety management, and therapeutic potential. We continue to follow the data and publish our findings to share what we’ve learned, enable collaboration across the oncology community, and accelerate progress for patients.
featured publications.
PUBLICATION
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
PUBLICATION
A Phase 1b dose-escalation study of ZN-c3, a Wee1 inhibitor, in combination with chemotherapy (CT) in subjects with platinum-resistant or refractory ovarian, peritoneal, or fallopian tube cancer
PUBLICATION
Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a Phase 1 study of the WEE1 inhibitor ZN-c3